Alexander I. Velasquez 1/14/26 Alexander I. Velasquez 1/14/26

Virgin Galactic: Cash Runway Falls Short Of Its Commercialization Timeline

Is Virgin Galactic's ambitious 2026 commercial timeline realistic? This Q3 2025 analysis breaks down SPCE's $110M quarterly cash burn, impending liquidity gap, and the high risk of shareholder dilution before meaningful revenue arrives in 2027.

Alexander I. Velasquez 1/5/26 Alexander I. Velasquez 1/5/26

Niagen Bioscience: Why Discipline Matters In A Crowded Supplement Market

Niagen Bioscience stock analysis examining Tru Niagen demand, cash flow strength, disciplined capital allocation, and long-term risks in the competitive NAD+ supplement market.

Alexander I. Velasquez 11/15/25 Alexander I. Velasquez 11/15/25

Niagen Bioscience: A Breakout Quarter That Now Faces Its Biggest Market Shift In Years

Niagen Bioscience (NASDAQ:NAGE) Q3 2025 earnings delivered explosive growth in revenue, margins, and cash flow—just as NMN re-enters the NAD+ market. Here’s what investors need to know about this new competitive pressure.

Alexander I. Velasquez 9/8/25 Alexander I. Velasquez 9/8/25

Niagen Bioscience: A Great Company Suffering From Stock Dilution

Niagen Bioscience (NASDAQ:NAGE) has a debt-free balance sheet and Q2 beat show momentum—but heavy share dilution and a price ~133% above my DCF give the stock a hold rating.